The introduction and widespread use of biologic DMARDs, especially IL-6 inhibitors, have dramatically reduced the incidence and progression of AA amyloidosis in RA, as demonstrated in both Japanese and international cohorts [9,10,11]. Here, IL6 is linked to AA amyloidosis.